The Food and Drug Administration on Tuesday announced approval for Movantik (naloxegol), a treatment for opioid-induced constipation in adults.
Rx.com Community Healthcare Network on Friday announced the release of the Care Rx application.
Mylan announced that its subsidiary, Mylan Labs Limited, has signed an agreement with Gilead Science under which Mylan has been licensed the non-exclusive rights to manufacture and distribute sofosbuvir and the investigational single tablet regimen of ledipasvir/sofosbuvir in 91 developing countries.
Sharps Compliance Corp. and MedReturn on Monday announced that they have joined forces to launch MedSafe.
Lupin Limited and Salix Pharmaceuticals on Friday announced that they have entered into a definitive distribution agreement under which Salix has granted Lupin the exclusive right to market, distribute and sell certain Salix products in Canada.
Close to 100 million wearable, remote patient-monitoring devices will ship over the next five years, according to ABI Research, boosted by growing interest and awareness about the benefits of supporting healthcare away from the hospital and into patients’ homes.
Diplomat on Wednesday announced that it is partnering with area leaders to provide the necessary funding to expand Dr. Phil Zimbardo's Hero Imagination Project to the Flint, Mich., area.
The Pharmaceutical Research and Manufacturers of America on Thursday announced the recipients of the 2014 Research and Hope Awards.
Medivation and Astellas Pharma on Wednesday announced that the Food and Drug Administration approved a new use of Xtandi (enzalutamide) capsules to treat patients with metastatic castration-resistant prostate cancer.
The Food and Drug Administration approved Contrave (naltrexone hydrochloride and bupropion hydrochloride extended-release tablets) as a chronic weight-management option.